At the symposium, Chairman Bai Chen gave a detailed introduction to MoMed Biotech's development history, core technologies in AI-driven drug discovery, pipeline layout, and focused on elaborating on the progress of research projects in fields such as oncology and autoimmune diseases. Dr. Zhang Zhen, Deputy General Manager of T&K, also introduced the company. As a comprehensive pharmaceutical innovation enterprise specializing in the R&D, production, sales, and agency operation of pharmaceutical products and medical devices, as well as providing pharmaceutical technology services and transfers, T&K has achieved remarkable results in the pharmaceutical field through years of accumulation and efforts.

The two sides conducted discussions on pipeline complementarity and technical synergy space, and both agreed that there is potential for cooperation in areas such as joint R&D of innovative drugs and pipeline resource sharing. Dr. Zhang Zhen, Deputy General Manager of T&K, pointed out: "MoMed Biotech's AI technology and pipeline layout have many alignment points with our business directions, and we look forward to further exploring cooperation models." Dr. Bai Chen, Chairman of MoMed Biotech, also stated, "T&K's industrial foundation can provide strong support for technology transformation, and the cooperation prospects between the two sides are broad."

During the visit, the T&K delegation visited MoMed Biotech's R&D computer room and office environment, and watched the company's promotional video, gaining an in-depth and intuitive understanding of MoMed Biotech's technical strength, R&D team, and market advantages in the field of new drug research and development.

This visit and exchange have enabled T&K and MoMed Biotech to gain a more comprehensive understanding of each other, laying a solid foundation for future cooperation. It is believed that with the efforts of both sides, a broader cooperation prospect can be created, and they will work together in the field of new drug research and development!